Tipranavir/Ritonavir (500/200 mg and 500/100 mg) Was Virologically Non-Inferior to Lopinavir/Ritonavir (400/100 mg) at Week 48 in Treatment-Naïve HIV-1-Infected Patients: A Randomized, Multinational, Multicenter Trial

dc.creatorCooper, David A
dc.creatorCordery, Damien V
dc.creatorZajdenverg, Roberto
dc.creatorRuxrungtham, Kiat
dc.creatorArastéh, Keikawus
dc.creatorBergmann, Frank
dc.creatorNeto, José L de Andrade
dc.creatorScherer, Joseph
dc.creatorChaves, Ricardo L
dc.creatorRobinson, Patrick
dc.creatorStudy Team
dc.date.accessioned2018-12-12T18:13:47Z
dc.date.accessioned2023-09-05T15:30:27Z
dc.date.available2018-12-12T18:13:47Z
dc.date.available2023-09-05T15:30:27Z
dc.date.created2018-12-12T18:13:47Z
dc.date.issued2016
dc.identifierCOOPER, D. A. et al. Tipranavir/Ritonavir (500/200 mg and 500/100 mg) Was Virologically Non-Inferior to Lopinavir/Ritonavir (400/100 mg) at Week 48 in Treatment-Naïve HIV-1-Infected Patients: A Randomized, Multinational, Multicenter Trial. PloS one, v. 11, n. 1, p. e0144917, 2016.
dc.identifier1932-6203
dc.identifierhttps://www.arca.fiocruz.br/handle/icict/30539
dc.identifier10.1371/journal.pone.0144917
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/8666898
dc.languageeng
dc.publisherPublic Library of Science
dc.rightsopen access
dc.titleTipranavir/Ritonavir (500/200 mg and 500/100 mg) Was Virologically Non-Inferior to Lopinavir/Ritonavir (400/100 mg) at Week 48 in Treatment-Naïve HIV-1-Infected Patients: A Randomized, Multinational, Multicenter Trial
dc.typeArticle


Este ítem pertenece a la siguiente institución